|
Synonyms: ARGX-113 | efgartigimod alfa-fcab | Vyvgart®
efgartigimod alfa is an approved drug (FDA (2021), EMA (2022))
Compound class:
Antibody
Comment: Efgartigimod alfa (ARGX-113) is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G (IgG) autoantibodies [6]. It binds to the IgG receptor, major histocompatibility complex class I-like Fc receptor (FcRn, the protein product of the FCGRT gene). Efgartigimod alfa inactivates FcRn's IgG binding ability (the FcRn-IgG interaction normally protects IgG from degradation) thus facilitating accelerated catabolism of native pathogenic autoantibodies [3,5]. The mechanism of this drug action is discussed more comprehensively in Roopenian and Akilesh (2007) [4] and Vaccaro et al. (2005) [7].
|
| No information available. |
Summary of Clinical Use ![]() |
| The reference version of efgartigimod (efgartigimod alfa-fcab; ARGX-113) was advanced to clinical evaluations in patients with myasthenia gravis (MG), pemphigus vulgaris and primary immune thrombocytopenia. Click here to view ClinicalTrials.gov's registered ARGX-113 trials. ARGX-113 was granted FDA orphan drug designation for the treatment of MG in September 2017 [1]. In December 2021 the US FDA approved efgartigimod alfa-fcab (Vyvgart®) as a treatment for MG. EMA authorisation for Vyvgart® was issued in 2022. Efgartigimod was further investigated for efficacy in the treatment of autoimmune encephalitis, autoimmune myositis. primary immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy (CIDP). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04687072 | A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Phase 3 Interventional | argenx | ||
| NCT04812925 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Phase 3 Interventional | argenx | ||
| NCT05979441 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | Phase 3 Interventional | argenx | ||
| NCT07583641 | A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults | Phase 2 Interventional | argenx | ||